Canadian drugmaker Valeant will work with British competitor AstraZeneca on a potential treatment for psoriasis a few months after biotech giant Amgen said it was ending research on the drug because of a link to suicidal thoughts and behavior. Valeant could pay AstraZeneca as much as $445 million if the drug is successfully developed and approved and meets sales targets.